Treatment-resistant Depression
📧 Sign up to get email alerts when something new happens for Treatment-resistant Depression.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2020-10-19Clinical Trial Update: A Study to Evaluate the Efficacy, Safety and Tolerability of Fixed Doses of Intranasal Esketamine in Japanese Participants With Treatment Resistant Depression [Phase 2]
Phase 2 study in Japanese participants evaluated fixed-dose intranasal esketamine for treatment-resistant depression; the trial completed an…
-
CLINICAL_TRIALS trial_result · 2020-08-31Clinical Trial Update: Low Dose Intravenous Ketamine in Treatment Resistant Depression Patients [Phase 2]
Phase 2 clinical trial update evaluating low dose intravenous ketamine for treatment-resistant depression has completed with posted results.
-
FDA approval · 2020-07-31FDA Approved: SPRAVATO — Supplemental Application (Janssen Pharmaceuticals Inc.)
FDA approved a supplemental application for SPRAVATO (esketamine hydrochloride) submitted by Janssen Pharmaceuticals Inc.
-
CLINICAL_TRIALS withdrawal · 2019-12-18Clinical Trial Update: Neural and Antidepressant Effects of Propofol (Phase 2) [Phase 2, Phase 3]
A Phase 2/Phase 3 clinical trial examining neural and antidepressant effects of propofol for treatment resistant depression has been withdra…
-
CLINICAL_TRIALS trial_result · 2019-11-20Clinical Trial Update: Efficacy of Deep Anaesthesia With Isoflurane as a Fast-response Antidepressant Agent [Phase 2]
Phase 2 trial update investigating the efficacy of deep anesthesia with isoflurane as a fast-response antidepressant agent.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2019-09-10Clinical Trial Update: Evaluation of Schemes of Administration of Intravenous Ketamine in Depression [Phase 3]
A Phase 3 clinical trial evaluating different schemes of intravenous ketamine administration for treatment-resistant depression is ongoing/u…
-
CLINICAL_TRIALS trial_result · 2019-08-29Clinical Trial Update: Administration of Subanesthetic Dose of Ketamine and Electroconvulsive Treatment for Treatment Resistant Depression [NA]
A completed clinical trial evaluating subanesthetic ketamine plus electroconvulsive treatment for treatment resistant depression.
-
FDA approval · 2019-06-25FDA Approved: SPRAVATO — Supplemental Application (Janssen Pharmaceuticals Inc.)
FDA approved Janssen's supplemental application for SPRAVATO (esketamine hydrochloride), resulting in labeling changes for the product.
-
CLINICAL_TRIALS trial_result · 2019-05-21Clinical Trial Update: A Study of Intranasal Esketamine Plus an Oral Antidepressant for Relapse Prevention in Adult Participants With Treatment-resistant Depression [Phase 3]
This Phase 3 trial evaluated intranasal esketamine plus an oral antidepressant for relapse prevention in adults with treatment-resistant dep…
-
FDA approval · 2019-05-09FDA Approved: SPRAVATO — Supplemental Application (Janssen Pharmaceuticals Inc.)
The FDA approved a supplemental application for SPRAVATO (esketamine hydrochloride) submitted by Janssen Pharmaceuticals.
-
CLINICAL_TRIALS trial_result · 2019-04-29Clinical Trial Update: A Long-term, Safety and Efficacy Study of Intranasal Esketamine in Treatment-resistant Depression [Phase 3]
A Phase 3 long-term safety and efficacy study of intranasal esketamine for treatment-resistant depression has completed, with results posted…
-
CLINICAL_TRIALS trial_result · 2019-04-24Clinical Trial Update: A Study to Evaluate the Efficacy, Safety, and Tolerability of Intranasal Esketamine Plus an Oral Antidepressant in Elderly Participants With Treatment-resistant Depression [Phase 3]
Phase 3 study evaluated intranasal esketamine plus an oral antidepressant in elderly patients with treatment-resistant depression; results w…
-
CLINICAL_TRIALS trial_result · 2019-04-19Clinical Trial Update: A Study to Evaluate the Efficacy, Safety, and Tolerability of Flexible Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression [Phase 3]
Phase 3 study evaluating the efficacy, safety, and tolerability of flexible doses of intranasal esketamine in combination with an oral antid…
-
CLINICAL_TRIALS trial_result · 2019-04-18Clinical Trial Update: A Study to Evaluate the Efficacy, Safety, and Tolerability of Fixed Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression [Phase 3]
Phase 3 trial results evaluate fixed-dose intranasal esketamine plus an oral antidepressant in adults with treatment-resistant depression; r…
-
FDA approval · 2019-03-05FDA Approved: SPRAVATO — Original Application (Janssen Pharmaceuticals Inc.)
FDA approved SPRAVATO (esketamine hydrochloride) nasal spray under an original NDA (NDA211243) for treatment-resistant depression in adults.…
-
CLINICAL_TRIALS trial_result · 2018-11-05Clinical Trial Update: Pharmacogenomics for Antidepressant Guidance and Education
Clinical trial on pharmacogenomics for antidepressant guidance and education in treatment-resistant depression was terminated with results p…
-
CLINICAL_TRIALS trial_result · 2018-09-17Clinical Trial Update: Low Field Magnetic Stimulation for Treatment Resistant Depression [NA]
A completed clinical trial investigating low field magnetic stimulation for treatment resistant depression, with results posted in 2018.
-
CLINICAL_TRIALS trial_result · 2018-09-12Clinical Trial Update: Deep Brain Stimulation (DBS) for Treatment-Resistant Depression (TRD) [NA]
Clinical trial update for deep brain stimulation in treatment-resistant depression shows completed status with posted results.
-
CLINICAL_TRIALS trial_result · 2018-09-04Clinical Trial Update: Monocentric Pilot Study, for a Randomized, Crossover, Blinded Trial: Comparison of the Therapeutic Efficacy of Low Frequency Repeated Transcranial Magnetic Stimulation on Cortical Area 9 Compared to Brodmann Area 46 in the Treatment of Depressive Disorders. [Phase 2]
Phase 2 randomized, crossover, blinded trial comparing low-frequency rTMS over cortical area 9 vs Brodmann area 46 for resistant depressive …
-
CLINICAL_TRIALS withdrawal · 2018-08-06Clinical Trial Update: Deep Brain Stimulation to Relieve Depression [Phase 3]
Phase 3 clinical trial of deep brain stimulation for treatment resistant depression was withdrawn.
-
CLINICAL_TRIALS trial_result · 2018-06-26Clinical Trial Update: Action of Ketamine in Treatment-Resistant Depression [Phase 2, Phase 3]
The document summarizes the completion status of Phase 2 and Phase 3 trials evaluating ketamine for treatment-resistant depression.
-
CLINICAL_TRIALS trial_result · 2018-06-11Clinical Trial Update: Nuedexta in Treatment-Resistant Major Depression [Phase 2]
Phase 2 trial evaluating Nuedexta (dextromethorphan/quinidine) for treatment-resistant major depressive disorder. Results were posted in Jun…
-
CLINICAL_TRIALS trial_result · 2018-04-17Clinical Trial Update: Double-Blind, Placebo-Controlled Trial of Ketamine Therapy in Treatment-Resistant Depression (TRD) [Phase 2]
Phase 2 double-blind, placebo-controlled trial evaluating ketamine therapy for treatment-resistant depression; results were posted in 2018.
-
CLINICAL_TRIALS trial_result · 2017-12-08Clinical Trial Update: Implementation Trial of Evidence Based Practices for Mood Disorders [NA]
Completion of an implementation trial evaluating evidence-based practices for mood disorders, including bipolar disorder and treatment-resis…
-
CLINICAL_TRIALS trial_result · 2017-09-13Clinical Trial Update: Comparing Ketamine and Propofol Anesthesia for Electroconvulsive Therapy [Phase 4]
A Phase 4 clinical trial compared ketamine versus propofol anesthesia for electroconvulsive therapy in treatment-resistant depression; the s…